Anadis clinical trial gets go-ahead

By Dylan Bushell-Embling
Wednesday, 03 September, 2008

The Israeli Ministry of Health has approved Anadis' (ASX:ANX) clinical protocol, clearing the way for trials of its mucositis treatment to begin within a month.

Mucostisis is a significant side effect of cancer therapy, experienced by between 20 and 100 per cent of patients, depending on the type of cancer and treatment.

Effects include painful mouth ulcerations and severe gastrointestinal symptoms.

The Anadis drug contains a unique formulation of Anadis' immune milk-derived anti LPS antibodies as well as other bioactives, and will be delivered using Anadis' oral delivery technology.

Anadis was recently awarded a grant from Vistech to help fund the drug development program.

Related News

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd